Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NGM 621

Next Previous
Drug Profile

NGM 621

Alternative Names: NGM 621

Latest Information Update: 11 Jan 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NGM Biopharmaceuticals
  • Class Antibodies; Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Complement C3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Dry age-related macular degeneration; SARS-CoV-2 acute respiratory disease

Highest Development Phases

  • Phase II Dry age-related macular degeneration
  • Discontinued SARS-CoV-2 acute respiratory disease

Most Recent Events

  • 09 Jan 2023 NGM 621 is available for licensing as of 09 Jan 2023. http://www.ngmbio.com 9378300
  • 01 Jan 2023 Discontinued - Phase-I/II for SARS-COV-2 acute respiratory disease in Australia (IV)
  • 01 Jan 2023 NGM Biopharmaceuticals and Merck option agreement expired unexercised leading to return of rights to NGM Biopharmaceuticals

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top